TP53 and endometrioid adenocarcinoma: For example, a poorly differentiated endometrioid carcinoma that falls into the CNH group (with TP53 mutations) would have a markedly different prognosis and treatment strategy compared to that in the POLE ultramutated or copy-number low groups [34].